熱門資訊> 正文
飞利浦将收购SpectraWAVE，扩大人工智能支持的冠状动脉成像和生理评估产品组合;未披露交易条款
2025-12-15 15:06
- Acquisition of SpectraWAVE's next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled angio-based FFR technology that delivers rapid, accurate coronary physiology assessment from a single angiogram [1]
- SpectraWAVE's technologies have the potential to significantly increase adoption of coronary intravascular imaging and physiological assessment, especially when combined with Philips' industry-leading Azurion image-guided therapy platform, supporting better outcomes [2] for more cardiac patients
- Acquisition will expand Philips' existing intravascular imaging and physiological assessment device portfolio, featuring Eagle Eye Platinum digital IVUS and OmniWire iFR technology, to create a comprehensive offering in intravascular imaging and physiology solutions
推薦文章
打新攻略 | 2025港股IPO收官戰！6只招股+9只待上市+6只聆訊！打新資金如何巧妙「吃大肉」？
新股申購 | 迅策、五一視界、英矽智能、美聯股份、卧安機器人以及林清軒六隻新股今起招股！
華盛早報 | 甲骨文融資告吹，重燃AI擔憂帶崩美股！納指跌近2%；特朗普今日10點發聲涉及26年政策
年末貨幣政策「壓軸大戲」：歐洲四央行同日登場，僅一家有望降息？
評級巨頭入局！穆迪擬推穩定幣評級體系，錨定儲備資產與贖回風險
壁仞科技衝擊「港股GPU第一股」：手握總價超8億的約束力訂單
美光科技：AI領域存儲器需求居高不下，公司營收預計大幅增長
12月18日外盤頭條：美光科技公佈強勁營收展望 亞馬遜重組AI部門 美欲借新一輪制裁施壓俄接受和平協議
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
